

Communiqué from the Annual General Meeting 2017

At the SpectraCures AGM held in Lund on 23 May 2017, the following decisions were taken.

Decisions concerning the adoption of the income statement and balance sheet, etc.

The AGM resolved to adopt the income statement and balance sheet for the financial year 2016. The Board of Directors and the Managing director were granted discharge for the financial year 2016. No dividend is paid for the financial year 2016.

Election of the Board of Directors and auditors:

the AGM resolved to re-elect the ordinary board members Ingemar Kihlström, Masoud Khayyami, Stefan Andersson-Engels, Katarina Svanberg and Sune Svanberg, and re-election of deputy board member Johannes Swartling. Ingemar Kihlström was re-elected as Chairman of the board.

The AGM resolved to re-elect the authorized public accountant Elena Entina and the approved auditor Berit Holmgren for the period until the end of the AGM 2018.

Decisions regarding fees:

the AGM resolved that fees to the Board of Directors shall be paid at SEK 200 000 to the Chairman of the board and with a price base amount to each other board members who are not employees of the company.

The auditors' fees shall be paid according to approved invoices.

Decision regarding authorisation of the Board of Directors to decide on the issue of shares, warrants and/or convertibles.

The AGM decided to authorize the Board, on one or more occasions until the next AGM, to make a decision to increase the company's share capital with a maximum of SEK 2 500 000 by new issue of no more than 25 000 000 shares, issue a maximum of 25 000 000 warrants and/or include convertible loan of not more than 25 000 000 convertible bonds. The Board of Directors shall be able to decide on the issue of shares, warrants and/or convertibles with deviation from the shareholders' preferential rights and/or with the provision for a report, set-off or otherwise with conditions in accordance with Chapter 2, section 5, second paragraph, 1-3 The Swedish Companies Act (2005:551).

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.